The Wayback Machine - http://web.archive.org/web/20260217011945/https://finance.yahoo.com/sectors/healthcare/
Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.
Market Cap
7.59T
Market Weight
9.74%
Industries
11
Companies
1137
Healthcare S&P 500 ^GSPC
Chart Range Bar
Loading chart for Healthcare

Day Return

Sector
0.66%
S&P 500
0.05%

YTD Return

Sector
4.88%
S&P 500
0.87%

1-Year Return

Sector
14.72%
S&P 500
12.96%

3-Year Return

Sector
22.34%
S&P 500
67.12%

5-Year Return

Sector
24.29%
S&P 500
73.89%

Note: Sector performance is calculated based on the previous closing price of all sector constituents

Industries in This Sector

Select an Industry for a Visual Breakdown

IndustryMarket WeightYTD Return
All Industries
100.00%
4.88%
Drug Manufacturers - General
42.79%
18.82%
Biotechnology
12.17%
0.52%
Medical Devices
11.25%
-2.55%
Diagnostics & Research
9.52%
-7.63%
Healthcare Plans
7.58%
-7.59%
Medical Instruments & Supplies
6.51%
-5.93%
Medical Distribution
3.25%
9.31%
Medical Care Facilities
3.24%
11.97%
Drug Manufacturers - Specialty & Generic
2.60%
2.92%
Health Information Services
1.08%
-41.48%
Pharmaceutical Retailers
0.00%
-15.91%

Note: Percentage % data on heatmap indicates Day Return

All Industries

Drug Manufacturers - General
-1.46%
Biotechnology
0.20%
Medical Devices
-0.07%
Diagnostics & Research
-0.24%
Healthcare Plans
-0.57%
Medical Instruments & Supplies
-0.08%
Medical Distribution
-0.25%
Medical Care Facilities
-0.12%
Drug Manufacturers - Specialty & Generic
1.21%
Health Information Services
0.58%
Pharmaceutical Retailers
1.25%

<= -3

-2

-1

0

1

2

>= 3

Largest Companies in This Sector

View More
Table View
Heatmap View
Name
Last Price
1Y Target Est.
Market Weight
Market Cap
Day Change %
YTD Return
Avg. Analyst Rating
1,040.00 1,201.63 12.93% 932.315B +0.33% -3.23%
Buy
243.45 231.25 8.13% 586.69B -0.45% +17.64%
Buy
231.50 245.33 5.67% 409.15B +1.76% +1.32%
Buy
121.41 124.89 4.20% 303.256B +1.82% +15.34%
Buy
293.19 364.62 3.68% 265.583B +3.10% -11.18%
Buy
369.19 345.56 2.76% 198.993B +0.82% +12.80%
Buy
112.68 133.39 2.72% 196.115B +1.09% -10.06%
Buy
154.98 153.08 2.67% 192.281B +2.09% +26.27%
Buy
504.82 666.46 2.63% 189.665B -0.98% -12.88%
Buy
485.84 611.82 2.39% 172.536B +1.51% -14.22%
Buy

Investing in the Healthcare Sector

Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds

ETF Opportunities

View More
Name
Last Price
Net Assets
Expense Ratio
YTD Return
157.67 40.98B 0.08% +1.85%
290.39 19.812B 0.09% +0.88%
172.55 8.534B 0.44% +2.24%
122.86 8.336B 0.35% +0.76%
100.95 4.621B 0.40% +3.64%

Mutual Fund Opportunities

View More
Name
Last Price
Net Assets
Expense Ratio
YTD Return
207.90 39.263B 0.32% +1.63%
87.66 39.263B 0.32% +1.63%
145.29 19.812B 0.09% +0.94%
11.18 15.226B 0.00% +0.66%
134.20 15.226B 0.00% +0.74%

Healthcare Research

View More

Discover the Latest Analyst and Technical Research for This Sector

  • Analyst Report: ResMed Inc.

    ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

    Rating
    Price Target
     
  • Analyst Report: IDEXX Laboratories, Inc.

    Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

    Rating
    Price Target
     
  • Analyst Report: ICU Medical, Inc.

    ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

    Rating
    Price Target
     
  • Analyst Report: Bio-Techne Corporation

    Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

    Rating
    Price Target
     

From the Community

Healthcare News